Profile data is unavailable for this security.
About the company
Probi AB is a Sweden-based company engaged in the probiotics research and development. The Company’s activities are divided into two business areas: Functional Foods, which focuses on the probiotics application in food in partnership with food companies; and Consumer Healthcares, which develops, commercializes and sells Probi probiotics in collaboration with a range of entities, such as pharmaceutical companies and firms related to the production of probiotics and self-care goods. Its brands portfolio comprises two trademarks: Probi Digestis and Probi Defendum. The Company's partners include Danone, Skanemejerier, NextFoods, Sanum Polska, Heinz, Kraft Foods, and Institut Rosell, among others. The Company is a parent of Probi Food AB and Probi Feed AB.
- Revenue in SEK (TTM)607.54m
- Net income in SEK-602.00k
- Incorporated1991
- Employees167.00
- LocationProbi ABIdeongatan 1ALUND 223 70SwedenSWE
- Phone+46 462868920
- Fax+46 462868928
- Websitehttps://probi.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Diamyd Medical AB | 282.00k | -120.18m | 1.21bn | 26.00 | -- | 6.23 | -- | 4,280.08 | -1.41 | -1.41 | 0.0033 | 1.91 | 0.0014 | -- | 6.56 | 11,280.00 | -59.77 | -25.46 | -66.19 | -28.37 | -4,930.85 | -1,419.23 | -42,617.73 | -5,896.43 | -- | -130.78 | 0.1176 | -- | 20.26 | -5.54 | -12.13 | -- | -- | -- |
Arcticzymes Technologies ASA | 117.67m | 18.52m | 1.31bn | 61.00 | 70.24 | 4.29 | 52.68 | 11.12 | 0.3702 | 0.3702 | 2.35 | 6.07 | 0.3618 | 0.5941 | 2.43 | -- | 5.69 | 15.52 | 6.12 | 17.16 | 95.02 | 96.69 | 15.74 | 33.10 | 12.43 | -- | 0.0392 | -- | -13.16 | 12.24 | -43.02 | -- | 47.93 | -- |
Hansa Biopharma AB | 165.88m | -844.88m | 1.44bn | 166.00 | -- | -- | -- | 8.67 | -16.07 | -16.07 | 3.15 | -7.10 | 0.1424 | 64.03 | 1.86 | 987,386.90 | -72.51 | -47.96 | -92.27 | -56.12 | 56.80 | 64.18 | -509.33 | -835.04 | 2.55 | -9.65 | 1.65 | -- | -13.22 | 109.06 | -36.09 | -- | -35.24 | -- |
Photocure ASA | 495.32m | 264.15k | 1.49bn | 106.00 | 7,715.88 | 3.11 | 53.74 | 3.00 | 0.0072 | 0.0072 | 18.58 | 17.79 | 0.7001 | 0.8203 | 9.37 | -- | 0.0375 | -3.09 | 0.0429 | -3.56 | 94.78 | 93.64 | 0.0535 | -5.19 | 4.32 | -- | 0.00 | -- | 27.35 | 22.50 | 100.37 | -- | 49.83 | -- |
BioInvent International AB | 71.46m | -330.30m | 1.65bn | 111.00 | -- | 1.26 | -- | 23.16 | -5.02 | -5.02 | 1.09 | 19.90 | 0.0459 | -- | 5.16 | 643,792.80 | -21.23 | -17.50 | -22.40 | -18.64 | -- | -- | -462.22 | -131.63 | 14.77 | -- | 0.0174 | -- | -78.09 | 13.14 | -677.13 | -- | 28.17 | -- |
Egetis Therapeutics AB (publ) | 57.50m | -326.80m | 1.68bn | 27.00 | -- | 3.08 | -- | 29.26 | -1.28 | -1.28 | 0.224 | 1.86 | 0.087 | 16.92 | 3.59 | 2,129,630.00 | -49.44 | -33.02 | -55.92 | -36.46 | 80.87 | -- | -568.00 | -357.72 | 3.32 | -- | 0.1688 | -- | 154.87 | 15.35 | -68.68 | -- | -- | -- |
Devyser Diagnostics AB | 169.30m | -53.60m | 1.71bn | 118.00 | -- | 4.44 | -- | 10.10 | -3.31 | -3.31 | 10.46 | 23.65 | 0.335 | 1.59 | 5.53 | 1,434,746.00 | -10.65 | -8.97 | -12.00 | -10.15 | 85.53 | 80.14 | -31.78 | -23.91 | 5.11 | -- | 0.1626 | -- | 33.71 | 28.59 | -16.64 | -- | 44.59 | -- |
Genovis AB | 158.23m | 61.50m | 1.87bn | 37.00 | 30.34 | 9.78 | 26.20 | 11.79 | 0.9394 | 0.9394 | 2.42 | 2.91 | 0.7203 | -- | -- | 4,276,514.00 | 27.99 | 18.56 | 30.74 | 21.45 | 72.20 | 65.51 | 38.87 | 23.88 | -- | -- | -- | -- | 54.54 | 35.56 | 449.56 | -- | -- | -- |
Vicore Pharma Holding AB | 0.00 | -310.94m | 1.93bn | 24.00 | -- | 4.24 | -- | -- | -3.24 | -3.24 | 0.00 | 4.08 | 0.00 | -- | -- | 0.00 | -74.40 | -58.65 | -83.09 | -65.58 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.81 | -- | -- | -- |
Nanoform Finland Oyj | 29.97m | -242.46m | 1.97bn | 165.00 | -- | 2.52 | -- | 65.89 | -0.2674 | -0.2674 | 0.0331 | 0.8535 | 0.0287 | 138.93 | 4.11 | 15,548.42 | -23.22 | -27.13 | -25.12 | -29.48 | -507.09 | -604.26 | -809.08 | -1,023.70 | 8.16 | -- | 0.0964 | -- | -26.41 | 61.31 | 5.98 | -- | 53.92 | -- |
Probi AB | 607.54m | -602.00k | 2.38bn | 167.00 | -- | 1.67 | 24.82 | 3.92 | -0.0528 | -0.0528 | 53.32 | 125.16 | 0.3885 | 3.23 | 6.52 | 3,797,144.00 | -0.0385 | 4.64 | -0.0407 | 4.98 | 32.39 | 42.04 | -0.0991 | 9.83 | 6.22 | -- | 0.0353 | 21.42 | 1.52 | 0.7684 | -58.60 | -26.09 | 31.01 | -- |
Holder | Shares | % Held |
---|---|---|
Fj�rde AP-fondenas of 31 Dec 2023 | 1.06m | 9.28% |
Swedbank Robur Fonder ABas of 31 Dec 2022 | 206.74k | 1.81% |
SEB Investment Management AB (Denmark)as of 28 Feb 2022 | 97.02k | 0.85% |
Handelsbanken Fonder ABas of 31 Mar 2024 | 69.42k | 0.61% |
Nordea Investment Management AB (Finland)as of 31 Aug 2023 | 67.24k | 0.59% |
Deka Investment GmbHas of 31 Dec 2023 | 60.98k | 0.54% |
SEB Investment Management ABas of 28 Mar 2024 | 59.10k | 0.52% |
Skandia Investment Management ABas of 29 Feb 2024 | 18.29k | 0.16% |
MFS International (UK) Ltd.as of 31 Mar 2024 | 16.60k | 0.15% |
Storebrand Asset Management ASas of 31 Jan 2024 | 4.20k | 0.04% |